These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38777770)

  • 21. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    Clin Exp Hepatol; 2021 Jun; 7(2):172-177. PubMed ID: 34295984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
    Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
    J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction-associated steatotic liver disease.
    Nakano M; Kawaguchi M; Kawaguchi T; Yoshiji H
    Hepatol Res; 2024 Jul; 54(7):655-666. PubMed ID: 38294999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT.
    Lee J; Byrne CJ; Brennan PN; MacPherson I; Dow E; Dillon JF
    Ann Hepatol; 2024; 29(2):101280. PubMed ID: 38219950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.
    Nakamura A; Kagaya Y; Saito H; Kanazawa M; Sato K; Miura M; Kondo M; Endo H
    J Atheroscler Thromb; 2023 May; 30(5):443-454. PubMed ID: 35768226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
    N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients.
    Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
    Clin Exp Hepatol; 2022 Dec; 8(4):278-283. PubMed ID: 36683866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study.
    Shima H; Tashiro M; Inoue T; Okada K; Okamoto T; Wariishi S; Doi T; Minakuchi J
    Cureus; 2024 Apr; 16(4):e57777. PubMed ID: 38715994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
    Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
    Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
    Li C; Wang T; Song J
    Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.
    Hirano T; Hayashi T; Sugita H; Tamasawa A; Goto S; Tomoyasu M; Yamamoto T; Ohara M; Terasaki M; Kushima H; Ito Y; Yamagishi SI; Mori Y
    J Diabetes Investig; 2023 Dec; 14(12):1401-1411. PubMed ID: 37647503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome.
    Nakamura A; Kagaya Y; Saito H; Kanazawa M; Sato K; Miura M; Kondo M; Endo H
    Heart Vessels; 2024 Jun; 39(6):486-495. PubMed ID: 38393377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes.
    Hoshino T; Ishizuka K; Toi S; Seki M; Kitagawa K
    J Atheroscler Thromb; 2022 Jul; 29(7):1020-1030. PubMed ID: 34248089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
    Takahashi Y; Seko Y; Yamaguchi K; Takeuchi K; Yano K; Kataoka S; Moriguchi M; Itoh Y
    J Gastroenterol Hepatol; 2023 Oct; 38(10):1743-1749. PubMed ID: 37221601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
    Komiya I; Yamamoto A; Sunakawa S; Wakugami T
    Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease.
    Ikeda S; Sugihara T; Hoshino Y; Matsuki Y; Nagahara T; Okano JI; Kitao S; Fujioka Y; Yamamoto K; Isomoto H
    Yonago Acta Med; 2020 Aug; 63(3):188-197. PubMed ID: 32884438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.